# BPC-157 TB-500: The Wolverine Blend Tracked Through the Research Record > BPC-157 TB-500 is the two-peptide Wolverine blend — BPC-157 plus the Ac-LKKTETQ fragment of Thymosin Beta-4. A dispatch console on the preclinical evidence, the regulatory status, and the channel both peptides move through. Two distinct peptides on one manifest — BPC-157 in the cytoprotective lane, TB-500 in the cell-migration lane. Every preclinical finding is logged to its source, every blend-level claim carries the honest no-human-data flag. ## BPC-157 and TB-500: what the Wolverine pairing actually is BPC-157 TB-500 is not one molecule. It is a research-community pairing of two distinct synthetic peptides shipped on a single manifest, marketed and discussed under the name "Wolverine." BPC-157 (Body Protection Compound 157) is a 15-amino-acid pentadecapeptide — sequence `GEPPPGKPADDAGLV`, molecular weight `~1419.5 Da`, `CAS 137525-51-0` — derived from a partial sequence of a protein found in human gastric juice [1]. TB-500 is a synthetic N-acetylated heptapeptide, `Ac-LKKTETQ`, molecular weight `~889 Da`, corresponding to residues 17-23 of the 43-residue protein Thymosin Beta-4 [7]. The blend has no single molecular weight, no CAS number, and no standardized composition. Commercial research-product vials commonly pair the two at fixed combined masses — for example `10 mg` BPC-157 with `10 mg` TB-500 — but no peer-reviewed study has defined a validated blend ratio [6]. The two values above describe the two constituents, not a unified entity. The pairing is rationalized as a two-mechanism tissue-repair manifest. BPC-157 runs the cytoprotective and pro-angiogenic lane: it up-regulates VEGFR2 and drives the VEGFR2-Akt-eNOS pathway [2]. TB-500 runs the cell-migration lane: its LKKTETQ motif binds monomeric G-actin 1:1 and sequesters it, regulating the cytoskeletal dynamics behind cell migration [3]. The two lanes are described as complementary — that is the basis of [the combination rationale and synergy claim](/research). Whether they actually converge on a greater-than-additive result is unestablished; no controlled combination study has been published. For the regulatory picture — FDA status and the WADA Prohibited List — see [BPC-157 TB-500 regulatory status](/regulatory-status). For how legally compounded access works, see [Wolverine legal status and 503A compounding](/legal-status). What follows on this site is editorial commentary on the published literature, organized as a two-lane manifest you can scan and verify. ## The 'Wolverine stack': combination rationale and the synergy claim The combination rationale is mechanistic complementarity, not a measured result. BPC-157 supplies a local cytoprotective and pro-angiogenic signal through VEGFR2-Akt-eNOS and growth-hormone-receptor-driven fibroblast proliferation [2]. TB-500 / Thymosin Beta-4 supplies an intracellular actin-sequestration signal that regulates cell migration and re-epithelialization [3][4]. On paper the two pathways are largely non-overlapping, which is why proponents describe stacking them. The synergy claim is a theoretical extrapolation from each peptide's separately characterized mechanism. No peer-reviewed study defines a synergistic dose, ratio, or endpoint for the two given together [11]. The most recent systematic review of BPC-157 — 36 studies, only one in humans — makes no mention of TB-500 or any combination [10]. "Synergy" is an inference drawn across two literatures, not a finding lifted from one experiment. ### Why are BPC-157 and TB-500 combined (the Wolverine stack)? The rationale is complementary mechanisms: BPC-157 supplies a local cytoprotective and pro-angiogenic signal (VEGFR2-Akt-eNOS) while TB-500 supplies an actin-sequestration signal driving cell migration [2][3]. The complementarity is theoretical. No controlled combination study has defined a synergistic dose, ratio, or endpoint for the pairing [11]. ## What this manifest tracks This page opens the manifest; the rest of the site routes the detail. [What the research literature shows](/research) breaks each preclinical finding out by lane — the BPC-157 tendon and angiogenesis studies, the TB-500 / Thymosin Beta-4 actin and wound-healing studies — and flags every blend-level gap. The [research dosing context](/dosage) covers the animal-model doses, [reconstitution and half-life](/dosage), and the routes studied, with the honest note that no validated blend dose exists. The FAQ collects the [safety and the tumor-signal concern](/faq). Every quantitative claim resolves to the [full reference list](/references). The register here is deliberately sober. The negative space on this manifest — no controlled blend trial, no validated dose, an identity caveat that doubles inside the pairing — is itself part of the record, and it is logged in the same ink as the findings. --- A two-lane dispatch manifest on the BPC-157 and TB-500 record — every constituent finding logged to its study, every blend-level claim cleared as no-human-data, with no clinic behind the console and nothing here routed for sale.